您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > (±)-Efavirenz-d5
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
(±)-Efavirenz-d5
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
(±)-Efavirenz-d5图片
包装:1mg
规格:98%
市场价:7097元
分子量:320.7

产品介绍
A neuropeptide with diverse biological activities
货号:ajcx20866
CAS:1132642-95-5
分子式:C14H4ClD5F3NO2
分子量:320.7
溶解度:DMF: 20 mg/ml,DMSO: 14 mg/ml,Ethanol: 20 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

(±)-Efavirenz-d5is intended for use as an internal standard for the quantification of efavirenz by GC- or LC-MS. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to wild-type and mutant HIV-1 RTs (Kis = 2.93 and 3.85-56.5 nM, respectively).1It inhibits wild-type and mutant HIV-1 viral replication in MT-4 human T lymphoid cells (IC95s = 1.5-1,500 nM). Efavirenz also prevents RNA plus-strand initiation with an IC50value of 17 nM.2In vivo, efavirenz reduces HIV-1 cDNA in spleen of HIV-1-challenged HIV-susceptible transgenic rats.3Formulations containing efavirenz have been used in combination therapy for the treatment of HIV-1.4,5


1.Young, S.D., Britcher, S.F., Tran, L.O., et al.L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptaseAntimicrob. Agents Chemother.39(12)2602-2605(1995) 2.Grobler, J.A., Dornadula, G., Rice, M.R., et al.HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitroJ. Biol. Chem.282(11)8005-8010(2007) 3.Goffinet, C., Allespach, I., and Keppler, O.T.HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcriptionProc. Natl. Acad. Sci. U.S.A.104(3)1015-1020(2007) 4.Sheran, M.The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIVHIV Clin.Trials6(3)158-168(2005) 5.Rakhmanina, N.Y., and van den Anker, J.N.Efavirenz in the therapy of HIV infectionExpert Opin. Drug Metab. Toxicol.6(1)95-103(2010)